CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales
Open Access
- 18 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 3 (1) , dlaa112
Abstract
Carbapenems are considered the drugs of choice for the treatment of serious infections caused by ceftriaxone-resistant Enterobacterales. However, because of the dramatic increase in carbapenem-resistant organisms worldwide, finding alternatives to carbapenems is a must. The potential options include β-lactam/β-lactamase inhibitor combinations, temocillin, cephamycins and some non-β-lactam drugs. The most controversial is piperacillin/tazobactam; the results of the MERINO trial are challenged because the isolates of patients with worse outcomes were frequently not susceptible to piperacillin/tazobactam when studied by reference methods, and also because the drug was not administered in extended infusion. Other potential options are briefly discussed. We conclude that carbapenems are not necessary for all patients with infections caused by ceftriaxone-resistant Enterobacterales.Keywords
This publication has 22 references indexed in Scilit:
- Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trialsJournal of Antimicrobial Chemotherapy, 2016
- A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2016
- Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysisJournal of Antimicrobial Chemotherapy, 2015
- Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis ModelAntimicrobial Agents and Chemotherapy, 2013
- -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective CohortsClinical Infectious Diseases, 2011
- Efficacy and safety of tigecycline: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2011
- Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactamInternational Journal of Antimicrobial Agents, 2008
- Community Infections Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coliArchives of internal medicine (1960), 2008
- Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trialsJournal of Antimicrobial Chemotherapy, 2007
- Antibiotic Resistance—Squeezing the Balloon?JAMA, 1998